Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05709574 · ClinicalTrials.gov registry record · Phase 2
Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer
A Phase 2 study of Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, sponsored by University of Arizona.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05709574 is a Phase 2 study of Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 10 participants, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05709574, a Phase 2 study of Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the ability of Tadalafil alone and in combination with neoadjuvant FLOT (5-Fluorouracil, Oxaliplatin, and Docetaxel) chemotherapy to suppress myeloid derived suppressor cells (MDSCs) in patients with resectable gastric or gastroesophageal junction adenocarcinoma. Resectable means the tumor may be removed through surgical intervention. Neoadjuvant chemotherapy is chemotherapy received before the primary course of treatment i.e.surgical intervention. The main questions it aims to answer are: * Is Tadalafil treatment with FLOT feasible and safe? * How does tadalafil treatment with FLOT affect the tumor microenvironment (TME)? * Will 8 weeks of neoadjuvant exposure to tadalafil with chemotherapy reduce MDSCs in the TME? Participants will receive Tadalafil for 14 days followed by combination of Tadalafil + FLOT for approximately 8 weeks as a part of standard of care neoadjuvant treatment in the window between cancer diagnosis and surgical intervention to remove their tumor. Tumor tissue, blood, and urine will be collected at the start of the study, after 2 weeks of treatment with Tadalafil alone, and around the time of surgical intervention. Saliva will also be collected at the start of the study.
Conditions Studied
Interventions
- DRUG Tadalafil 20 MG
Study Locations (1)
Arizona
- Arizona Cancer Center at UMC North/University Medical Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2023-04-20 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05709574
The ClinicalTrials.gov registry entry for NCT05709574 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 47 other Gastric Adenocarcinoma trials with a reported enrollment target (96% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Gastric Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Tadalafil 20 MG is the first listed.
NCT05709574 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT05709574 about?
NCT05709574 is a clinical study titled "Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer". The goal of this clinical trial is to assess the ability of Tadalafil alone and in combination with neoadjuvant FLOT (5-Fluorouracil, Oxaliplatin, and Docetaxel) chemotherapy to suppress myeloid derived suppressor cells (MDSCs) in patients with resectable gastric or gastroesophageal junction adenoca...
What is the current status of trial NCT05709574?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2023-04-20. Estimated completion is 2026-05-31.
What conditions does trial NCT05709574 study?
This clinical trial studies the following conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.
What interventions are being tested in trial NCT05709574?
The interventions under investigation include: Tadalafil 20 MG (DRUG).
Who is sponsoring clinical trial NCT05709574?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05709574 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
RECRUITING · Phase 2
-
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
RECRUITING · Phase 2
-
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RECRUITING · Phase 2
-
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Gastric Adenocarcinoma
All registered trials for this condition
Gastroesophageal Junction Adenocarcinoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.